This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received YAZ for dysmenorrhea. The objective of this study is to assess safety and efficacy of using YAZ in clinical practice. A total 3,000 patients will be recruited and followed 3 years since starting YAZ administration.
Study Type
OBSERVATIONAL
Enrollment
3,273
Patients in daily life treatment receiving YAZ for dysmenorrhea.
Unnamed facility
Multiple Locations, Japan
Incidence of adverse drug reactions and sever adverse events
Time frame: During YAZ administration, up to 3 years
Change from baseline in severity of dysmenorrhea at 6th cycles (28 days per cycle)
Time frame: Baseline and during YAZ administration, up to 3 years
Incidence of adverse events
Time frame: During YAZ administration, up to 3 years
Unpleasant physical symptoms collection
Time frame: Baseline and during YAZ administration, up to 3 years
Unpleasant psychological symptoms collection
Time frame: Baseline and during YAZ administration, up to 3 years
Analgesic drug for dysmenorrhea
Time frame: During YAZ administration, up to 3 years
QOL survey using Short-Form 36-Item Health Survey (SF-36)
Time frame: Baseline and at 6th - 8th cycles (28 datys per cycle)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.